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Abstract
Our intestinal microbiota comprises 100 trillion bacteria, exceeding our own eukaryotic cells. While the microbiota has incredible
health beneﬁts, changes in the normal ﬂora caused by inﬂammation, antibiotics or diet can negatively impact health and may
contribute to diseases such as inﬂammatory bowel disease (IBD) and obesity. Using healthy microbiota to treat individuals with
intestinal disease is not a new idea and fecal microbiota transplantation (FMT) has been used as a successful therapy in patients
suﬀering from Clostridium diﬃcile infection. Currently FMT is being considered as a treatment for patients with IBD. This editorial
will discuss the history of FMT and implications for treatment of other inﬂammatory intestinal diseases.
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Our gut microbiota comprises 100 trillion bacteria,
exceeding our own cells by ten-fold. The gut
microbiota has several functions, including digestion,
colonization resistance, maintenance of mucosal
integrity, and priming of the mucosal immune
response [1]. Disruption of the normal microbiota,
or dysbiosis, can impact immunity and result in
disease. This is best illustrated by Clostridium
diﬃcile infection (CDI), acquired when gut microbial
diversity and number are reduced by antibiotic
treatment. Antibiotic treatment compromises the
ability of the natural microbiota to resist colonization
by opportunistic pathogens, allowing resident C.
diﬃcile or ingested environmental C. diﬃcile spores
to dominate the intestinal tract, which leads
to diarrhea and inﬂammation associated with
pseudomembranous colitis. The close relationship
between gut microbiota and disease is also apparent
in IBD, such as Crohn’s disease and ulcerative colitis,
and alterations in the microbiota of IBD patients are
well documented [2-11].
C. diﬃcile is one of the most important causes
of nosocomial infections. In the last 10 - 15 years,
with the emergence of hypervirulent strains, there
has been an increase in prevalence and severity
of CDI [12]. Standard treatment for CDI involves
antibiotics such as metronidazole and vancomycin.
However, ~20 % of patients with an initial CDI
are unresponsive to antibiotic treatment [13,14].
Furthermore, despite the recommended treatment,
recurrence of disease is frequent [13-15]. There
are now alternative antibiotics such as ﬁdaxomicin,
which has a CDI cure rate similar to vancomycin and
shows improvement in its eﬃcacy against recurrent
CDI [16,17].
FMT is beginning to be recognized as an
alternative to antibiotic treatment for CDI. FMT
involves infusing bacteria from a healthy donor into
the gastrointestinal tract of the patient to reestablish
a normal gut ﬂora by repairing or replacing the
diseased ﬂora [18]. In veterinary medicine, this
process, called transfaunation, has been practiced
for decades [19]. The ﬁrst recorded performance of
FMT in humans was in the 1950s in patients with
fulminant pseudomembranous colitis later found
to be caused by recalcitrant CDI, who showed
“immediate and dramatic” responses [20]. Today
there are more than 500 patients who have been
treated for CDI with FMT with a cure rate of
~95% [21,22]. However, despite its eﬃcacy, FMT
has not become a widely used therapy for CDI,
mainly due to the “yuck factor” and lack of data
from randomized, controlled trials. Earlier this year,
eﬃcacy of FMT for recurrent CDI was conﬁrmed
by the ﬁrst randomized, controlled trial [23]. In
this study, FMT was signiﬁcantly more eﬀective in
treating recurrent CDI than vancomycin alone or in
combination with bowel lavage. Although the trial
was not blinded and had a small group size, it
provides impetus to address the other obstacles in
adopting FMT as a routine therapy. As an example,
there is growing interest in strategies to circumvent
the direct use of feces by substituting it with puriﬁed
intestinal bacterial cultures derived from a single
healthy donor [24,25]. Additionally, the need to
standardize the protocol for FMT is being recognized
[26].
Although FMT has been reported mostly in the
context of recalcitrant CDI, there are emerging
applications of FMT. With the evidence that speciﬁc
gut microbes can induce distinct immune responses
in the host and that there is reduced diversity of
the microbiota in patients with IBD [27-29], it is
not far-fetched to think that restoring a normal
microbiota will alleviate IBD. Indeed there are eight
cases of ulcerative colitis and one case of Crohn’s
2disease in which FMT led to remission [30-32].
Though not identical to the human disease, there are
animal models that mimic colitis and inﬂammation,
which demonstrated that susceptibility to colitis and
resistance to enteric infection are transferrable by
FMT [33-35].
With FMT in IBD still in its infancy, there are
lessons to learn from the more widely used FMT
for CDI. First, it is necessary to have controlled and
randomized clinical trials to address the eﬃcacy
of FMT in IBD. There are several uncontrolled
clinical trials that are ongoing; however, there has
yet to be a study with a control group. Second,
a standardized treatment protocol needs to be
established for stool processing, patient preparation
(i.e. antibiotic treatment pre-transplantation), and
delivery method. Lastly, the donor selection and
screening process must be robust and well
documented. This may be more important for
treatment of IBD than CDI, as multiple infusions
are typically necessary for the former [21], and
consistency between the repeated infusions would
be ideal. Current clinical trials will shed light on some
of these considerations and will help shape future
investigations on the therapeutic value of FMT for
IBD.
References
1. Berg RD: The indigenous gastrointestinal microﬂora. Trends
Microbiol 1996, 4: 430-435
2. Giaﬀer MH, Holdsworth CD, Duerden BI: The assessment of faecal
ﬂora in patients with inﬂammatory bowel disease by a simpliﬁed
bacteriological technique. J Med Microbiol 1991, 35: 238-243
3. Gophna U, Sommerfeld K, Gophna S, Doolittle WF, Veldhuyzen
van Zanten SJ: Diﬀerences between tissue-associated intestinal
microﬂoras of patients with Crohn's disease and ulcerative colitis. J
Clin Microbiol 2006, 44: 4136-4141
4. Krook A, Lindström B, Kjellander J, Järnerot G, Bodin L: Relation
between concentrations of metronidazole and Bacteroides spp in
faeces of patients with Crohn's disease and healthy individuals. J
Clin Pathol 1981, 34: 645-650
5. Lepage P, Seksik P, Sutren M, de la Cochetière MF, Jian R,  et al.:
Biodiversity of the mucosa-associated microbiota is stable along the
distal digestive tract in healthy individuals and patients with IBD.
Inﬂamm Bowel Dis 2005, 11: 473-480
6. Mangin I, Bonnet R, Seksik P, Rigottier-Gois L, Sutren M,  et al.:
Molecular inventory of faecal microﬂora in patients with Crohn's
disease. FEMS Microbiol Ecol 2004, 50: 25-36
7. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E,  et al.:
Reduced diversity of faecal microbiota in Crohn's disease revealed
by a metagenomic approach. Gut 2006, 55: 205-211
8. Van de Merwe JP, Schröder AM, Wensinck F, Hazenberg MP: The
obligate anaerobic faecal ﬂora of patients with Crohn's disease
and their ﬁrst-degree relatives. Scand J Gastroenterol 1988, 23:
1125-1131
9. Prindiville T, Cantrell M, Wilson KH: Ribosomal DNA sequence
analysis of mucosa-associated bacteria in Crohn's disease. Inﬂamm
Bowel Dis 2004, 10: 824-833
10.Scanlan PD, Shanahan F, O'Mahony C, Marchesi JR: Culture-
independent analyses of temporal variation of the dominant fecal
microbiota and targeted bacterial subgroups in Crohn's disease. J
Clin Microbiol 2006, 44: 3980-3988
11.Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P,  et al.:
Alterations of the dominant faecal bacterial groups in patients with
Crohn's disease of the colon. Gut 2003, 52: 237-242
12.Rupnik M, Wilcox MH, Gerding DN: Clostridium diﬃcile infection:
new developments in epidemiology and pathogenesis. Nat Rev
Microbiol 2009, 7: 526-536
13.Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I,  et al.:
Relatively poor outcome after treatment of Clostridium diﬃcile
colitis with metronidazole. Clin Infect Dis 2005, 40: 1586-1590
14.Zar FA, Bakkanagari SR, Moorthi KM, Davis MB: A comparison of
vancomycin and metronidazole for the treatment of Clostridium
diﬃcile-associated diarrhea, stratiﬁed by disease severity. Clin
Infect Dis 2007, 45: 302-307
15.Johnson S: Recurrent Clostridium diﬃcile infection: a review of risk
factors, treatments, and outcomes. J Infect 2009, 58: 403-410
16.Crook DW, Walker AS, Kean Y, Weiss K, Cornely OA,  et al.:
Fidaxomicin versus vancomycin for Clostridium diﬃcile infection:
meta-analysis of pivotal randomized controlled trials. Clin Infect Dis
2012, 55 Suppl 2: S93-103
17.Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A,  et al.:
Fidaxomicin versus vancomycin for Clostridium diﬃcile infection. N
Engl J Med 2011, 364: 422-431
18.Borody TJ, Khoruts A: Fecal microbiota transplantation and
emerging applications. Nat Rev Gastroenterol Hepatol 2011, 9:
88-96
19.Rager KD, George LW, House JK, DePeters EJ: Evaluation of rumen
transfaunation after surgical correction of left-sided displacement
of the abomasum in cows. J Am Vet Med Assoc 2004, 225: 915-920
20.EISEMAN B, SILEN W, BASCOM GS, KAUVAR AJ: Fecal enema as
an adjunct in the treatment of pseudomembranous enterocolitis.
Surgery 1958, 44: 854-859
21.Borody TJ, Campbell J: Fecal microbiota transplantation:
techniques, applications, and issues. Gastroenterol Clin North Am
2012, 41: 781-803
22.Gough E, Shaikh H, Manges AR: Systematic review of intestinal
microbiota transplantation (fecal bacteriotherapy) for recurrent
Clostridium diﬃcile infection. Clin Infect Dis 2011, 53: 994-1002
23.van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG,  et al.:
Duodenal infusion of donor feces for recurrent Clostridium diﬃcile.
N Engl J Med 2013, 368: 407-415
24.Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D,  et al. :Stool
substitute transplant therapy for the eradication of Clostridium
diﬃcile infection: 'RePOOPulating' the gut. Microbiome 2013, 1:3
25.Tvede M, Rask-Madsen J: Bacteriotherapy for chronic relapsing
Clostridium diﬃcile diarrhoea in six patients. Lancet 1989, 1:
1156-1160
26.Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC,  et al.: Treating
Clostridium diﬃcile infection with fecal microbiota transplantation.
Clin Gastroenterol Hepatol 2011, 9: 1044-1049
27.Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T,  et al.: Induction of
intestinal Th17 cells by segmented ﬁlamentous bacteria. Cell 2009,
139: 485-498
28.Mazmanian SK, Round JL, Kasper DL: A microbial symbiosis
factor prevents intestinal inﬂammatory disease. Nature 2008, 453:
620-625
29.Qin J, Li R, Raes J, Arumugam M, Burgdorf KS,  et al.: A human gut
microbial gene catalogue established by metagenomic sequencing.
Nature 2010, 464: 59-65
30.Bennet JD, Brinkman M: Treatment of ulcerative colitis by
implantation of normal colonic ﬂora. Lancet 1989, 1: 164
31.Borody TJ, George L, Andrews P, Brandl S, Noonan S,  et al.:Bowel-
ﬂora alteration: a potential cure for inﬂammatory bowel disease
and irritable bowel syndrome? Med J Aust 1989, 150: 604
32.Borody TJ, Warren EF, Leis S, Surace R, Ashman O: Treatment of
ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol
2003, 37: 42-47
33.Garrett WS, Lord GM, Punit S, Lugo-Villarino G, Mazmanian SK,  et
al.: Communicable ulcerative colitis induced by T-bet deﬁciency in
the innate immune system. Cell 2007, 131: 33-45
34.Willing BP, Vacharaksa A, Croxen M, Thanachayanont T, Finlay
BB: Altering host resistance to infections through microbial
transplantation. PLoS One 2011, 6: e26988
35.Ghosh S, Dai C, Brown K, Rajendiran E, Makarenko S,  et al.:
Colonic microbiota alters host susceptibility to infectious colitis
by modulating inﬂammation, redox status, and ion transporter
gene expression. Am J Physiol Gastrointest Liver Physiol 2011, 301:
G39-49
